CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 280 enrolled
Drug / intervention
MORF-057 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05611671
NCT05611671Phase 2Active
CompareCT.gov

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-2)

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)·interventional·Posted Nov 10, 2022·Updated Dec 15, 2025

In Brief

A Phase 2 clinical trial evaluating MORF-057 and Placebo for Inflammatory Bowel Diseases and Colitis, Ulcerative. Active but no longer recruiting, targeting 280 participants across 102 sites in 21 countries.

Detailed Summary

This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 in adult patients with moderately to severely active Ulcerative Colitis (UC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammatory Bowel Diseases, Colitis, Ulcerative
CountriesAustralia, Austria, Bulgaria, Czechia, Estonia, France, Georgia, Germany, Hungary, India, Israel, Italy, Latvia, Lithuania, Poland, Romania, Serbia, Slovakia, South Korea, Taiwan, United States
Collaborators--

Timeline

Phase 2Active
2023202420252026
First PostedNov 10, 2022
Enrollment StartNov 21, 2022
Primary CompletionNov 28, 2024
Study CompletionAug 1, 2026
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 3.6 years ago

Interventions

MORF-057drug

MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.

Placebodrug

Matching placebo (identical appearance to MORF-057) administered orally.